Outcomes | No. of patients with initial Cmin | No. of patients with maximal Cmin | ||||
---|---|---|---|---|---|---|
< 20 μg/mL | ≥20 μg/mL | P-value | < 20 μg/mL | ≥20 μg/mL | P-value | |
Early clinical response (n = 76) | 23/37 (62.2%) | 31/39 (79.5%) | 0.096 | – | – | – |
Clinical success at the end of therapy (n = 76) | 25/37 (67.6%) | 30/39 (76.9%) | 0.362 | 22/33 (66.7%) | 33/43 (76.7%) | 0.330 |
Microbiological success (n = 68) | 22/33 (66.7%) | 25/35 (71.4%) | 0.671 | 20/31 (64.5%) | 27/37 (73.0%) | 0.452 |
28 days mortality (n = 76) | 5/37 (13.5%) | 2/39 (5.1%) | 0.256 | 5/33 (15.2%) | 2/43 (4.7%) | 0.229 |